We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+5.7%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.14B
AUM Growth
-$69.7M
Cap. Flow
-$57.8M
Cap. Flow %
-5.05%
Top 10 Hldgs %
63.1%
Holding
46
New
5
Increased
8
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$31.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$8.97M
3
SAGE
Sage Therapeutics
SAGE
+$4.48M
4
SANA icon
Sana Biotechnology
SANA
+$4.32M
5
VERV
Verve Therapeutics
VERV
+$4M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$25M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$18.7M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$16.1M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$8.88M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAM
26
DELISTED
Avidity Biosciences
RNAM
$9.43M 0.82%
850,000
– –
TWST icon
27
Twist Bioscience
TWST
$6.29B
$9.21M 0.8%
450,000
-250,000
-36% -$3.75M
PRME icon
28
Prime Medicine
PRME
$508M
$5.38M 0.47%
367,175
-367,175
-50% -$5.13M
INCY icon
29
Incyte
INCY
$24B
$4.82M 0.42%
77,500
– –
SANA icon
30
Sana Biotechnology
SANA
$885M
$4.47M 0.39%
+750,000
New +$4.32M
SAGE
31
DELISTED
Sage Therapeutics
SAGE
$4.23M 0.37%
+90,000
New +$4.48M
GLUE icon
32
Monte Rosa Therapeutics
GLUE
$1.3B
$3.5M 0.31%
510,882
– –
TNGX icon
33
Tango Therapeutics
TNGX
$4.43B
$3.32M 0.29%
1,000,000
– –
LAB icon
34
Standard BioTools
LAB
$339M
$2.32M 0.2%
+1,200,000
New +$2.37M
ABSI icon
35
Absci
ABSI
$1.34B
$2.08M 0.18%
1,368,260
-4,025,000
-75% -$6.47M
EXAI
36
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$1.27M 0.11%
213,900
– –
OMIC
37
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.12M 0.1%
44,857
– –
MRTX
38
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$860K 0.08%
23,814
-486,186
-95% -$20M
LIAN
39
DELISTED
LianBio American Depositary Shares
LIAN
$471K 0.04%
206,415
– –
KRON
40
DELISTED
Kronos Bio
KRON
$213K 0.02%
123,839
– –
SCLX icon
41
Scilex Holding
SCLX
$46.1M
$131K 0.01%
+672
New +$185K
OPRX icon
42
OptimizeRx
OPRX
$123M
– –
-500,000
Closed -$7.32M
SRPT icon
43
CALL
Sarepta Therapeutics
SRPT
$1.68B
– –
-25,000
Closed -$3.45M
NVTA
44
DELISTED
Invitae Corporation
NVTA
– –
-1,038,388
Closed -$1.4M
DICE
45
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-310,000
Closed -$8.88M
RXDX
46
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-150,000
Closed -$16.1M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Casdin Capital held 46 positions worth $1.14B, down 5.7% from $1.21B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Casdin Capital withdrew a net $57.8M in Q2 2023, closing 5 positions and reducing 9 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Casdin Capital opened a new position in CATALENT, INC. worth $31.2M.

  • Casdin Capital's largest Q2 2023 buy was CATALENT, INC.: 720,000 shares worth $31.2M.
  • Casdin Capital added most to Structure Therapeutics in Q2 2023, an estimated $8.97M increase.
  • Casdin Capital's biggest Q2 2023 reduction was Illumina, cutting an estimated $25M.
  • Casdin Capital fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $16.1M.
  • Casdin Capital's ten largest holdings make up 63% of its $1.14B portfolio in Q2 2023.
  • Casdin Capital opened 5 new positions and closed 5 in Q2 2023.
  • Casdin Capital's portfolio value fell 5.7% quarter-over-quarter to $1.14B.

Based on Casdin Capital's 13F filing for Q2 2023, filed 14 Aug 2023.